T
Thomas C. Merigan
Researcher at Stanford University
Publications - 515
Citations - 34283
Thomas C. Merigan is an academic researcher from Stanford University. The author has contributed to research in topics: Interferon & Virus. The author has an hindex of 98, co-authored 514 publications receiving 33941 citations. Previous affiliations of Thomas C. Merigan include University of Arizona & Rockefeller Institute of Government.
Papers
More filters
Journal ArticleDOI
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
Jonathan M. Schapiro,Mark A. Winters,Fran Stewart,Bradley Efron,Jane Norris,Michael J. Kozal,Thomas C. Merigan +6 more
TL;DR: Squinavir was studied at twice and four times the currently licensed dose to determine the efficacy, safety, and pharmacokinetics of saquinvir and to identify the optimal dose of sa Quentinavir for future study both as monotherapy and in combination with other antiretroviral agents.
Journal ArticleDOI
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.
Hannah A. Valantine,Shao-Zhou Gao,Santosh Menon,Dale G. Renlund,Sharon A. Hunt,Philip E. Oyer,Edward B. Stinson,Byron W. Brown,Thomas C. Merigan,John S. Schroeder +9 more
TL;DR: TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers, and a randomized clinical trial is required to address this issue.
Journal Article
Frequency of Class I HLA-Restricted Anti-HIV CD8+ T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)
Clive M. Gray,Jody Lawrence,Jonathan M. Schapiro,John D. Altman,John D. Altman,Mark A. Winters,Meg Crompton,Muoi Loi,Smriti K. Kundu,Mark M. Davis,Thomas C. Merigan +10 more
TL;DR: Evidence is provided that persistently replicating viral populations are probably required to maintain high frequencies of HIV-1 epitope-specific CD8+ T cells in asymptomatic chronically infected individuals.
Journal ArticleDOI
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
David W. Haas,Laura M. Smeaton,Robert W. Shafer,Gregory K. Robbins,Gene D. Morse,Line Labbé,Grant R. Wilkinson,David B. Clifford,Richard T. D'Aquila,Victor De Gruttola,Richard B. Pollard,Thomas C. Merigan,Martin S. Hirsch,Alfred L. George,John P. Donahue,Richard B. Kim +15 more
TL;DR: Genetic variants predict plasma exposure to efavirenz and nelfinavir, and they may predict virologic failure and/or emergence of drug-resistant virus.
Journal ArticleDOI
Survival in chronic hepatitis B. An analysis of 379 patients.
Jed I. Weissberg,Ljudevit L. Andres,C. Smith,Sheila Weick,Joanne E. Nichols,Gabriel Garcia,William S. Robinson,Thomas C. Merigan,Peter B. Gregory +8 more
TL;DR: Survival data from 379 patients with chronic hepatitis B were analyzed to determine life expectancy for the patient from the time of first contact, and a multivariate analysis found age of 40 years or more, total bilirubin level of 1.5 mg/dLor more, ascites, and spider nevi to be factors that identified patients at a higher risk of death.